PMID- 37161387
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 23
IP  - 8
DP  - 2023 Jul-Dec
TI  - Self-reported efficacy and safety of infliximab and adalimumab biosimilars after 
      non-medical switch in patients with inflammatory bowel disease: results of a 
      multicenter survey.
PG  - 827-832
LID - 10.1080/14712598.2023.2211204 [doi]
AB  - BACKGROUND: Few data are available on subjective disease control and perception 
      of adverse events (AEs) during switching from original anti-TNF agents to 
      biosimilars. RESEARCH DESIGN AND METHODS: Hungarian patients with inflammatory 
      bowel disease were interviewed after a mandatory non-medical switch from an 
      infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) 
      originator to a biosimilar GP2017. Drug choice was based on patient's and 
      physician's decision. Subjective efficacy was measured using a 10-point scale, 
      and AEs were assessed. Difference in efficacy before and after the switch was 
      compared within and between the drugs. RESULTS: Seventy-three ADA and 106 IFX 
      switching patients were interviewed. Subjective efficacy of IFX biosimilar was 
      rated lower compared to IFX originator (8.72 +/- 1.68 vs. 7.77 +/- 2.34; p = 0.001). 
      The ADA biosimilar was rated higher than its originator (9.02 +/- 1.61 vs. 
      8.42 +/- 1.93; p = 0.017). Patients receiving ADA biosimilar were more satisfied 
      with the new treatment compared to IFX (p = 0.032). The incidence of new AEs was 
      85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, 
      respectively, p < 0.001). CONCLUSION: Subjective efficacy of switching to a 
      biosimilar was proven in case of ADA, while reduced efficacy was experienced with 
      IFX biosimilar. Perception of AEs was high and varied between biosimilars.
FAU - Sarlos, Patricia
AU  - Sarlos P
AUID- ORCID: 0000-0002-5086-9455
AD  - Department of Medicine, University of Pecs Medical School, Pecs, Hungary.
AD  - Institute for Translational Medicine, University of Pecs Medical School, Pecs, 
      Hungary.
FAU - Bikar, Alexander
AU  - Bikar A
AUID- ORCID: 0009-0004-2225-2193
AD  - Department of Medicine, University of Pecs Medical School, Pecs, Hungary.
FAU - Farkas, Nelli
AU  - Farkas N
AD  - Institute for Translational Medicine, University of Pecs Medical School, Pecs, 
      Hungary.
FAU - Resal, Tamas
AU  - Resal T
AD  - Department of Medicine, University of Szeged Albert Szent-Gyorgyi, Szeged, 
      Hungary.
FAU - Szepes, Zoltan
AU  - Szepes Z
AUID- ORCID: 0000-0002-9466-8719
AD  - Department of Medicine, University of Szeged Albert Szent-Gyorgyi, Szeged, 
      Hungary.
FAU - Farkas, Klaudia
AU  - Farkas K
AUID- ORCID: 0000-0003-0599-182X
AD  - Department of Medicine, University of Szeged Albert Szent-Gyorgyi, Szeged, 
      Hungary.
FAU - Nagy, Ferenc
AU  - Nagy F
AD  - Department of Medicine, University of Szeged Albert Szent-Gyorgyi, Szeged, 
      Hungary.
FAU - Vincze, Aron
AU  - Vincze A
AD  - Department of Medicine, University of Pecs Medical School, Pecs, Hungary.
FAU - Miheller, Pal
AU  - Miheller P
AD  - Department of Surgery, Transplantation and Gastroenterology, Semmelweis 
      University, Budapest, Hungary.
FAU - Molnar, Tamas
AU  - Molnar T
AUID- ORCID: 0000-0002-4913-7599
AD  - Department of Medicine, University of Szeged Albert Szent-Gyorgyi, Szeged, 
      Hungary.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230509
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - B72HH48FLU (Infliximab)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - FYS6T7F842 (Adalimumab)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Gastrointestinal Agents)
SB  - IM
MH  - Humans
MH  - Infliximab/adverse effects
MH  - *Biosimilar Pharmaceuticals/adverse effects
MH  - Adalimumab/adverse effects
MH  - Self Report
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - *Inflammatory Bowel Diseases/drug therapy
MH  - Treatment Outcome
MH  - Gastrointestinal Agents/adverse effects
OTO - NOTNLM
OT  - Inflammatory bowel disease
OT  - adalimumab
OT  - biosimilar
OT  - infliximab
OT  - non-medical switch
EDAT- 2023/05/10 06:42
MHDA- 2023/05/10 06:43
CRDT- 2023/05/10 03:51
PHST- 2023/05/10 06:43 [medline]
PHST- 2023/05/10 06:42 [pubmed]
PHST- 2023/05/10 03:51 [entrez]
AID - 10.1080/14712598.2023.2211204 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2023 Jul-Dec;23(8):827-832. doi: 
      10.1080/14712598.2023.2211204. Epub 2023 May 9.